Enhance patient care

Our mission to improve a patient’s quality of life by enabling them to benefit from personal insights at the genomic level of their disease, could never be accomplished without the commitment from care providers that offer their knowledge, experience, and wholehearted support to patients and their respective needs and wishes.

Through innovative molecular diagnostic tools, we are determined to empower care providers by making more information on the patient’s disease available that allows for personalized treatment decision-making. Precision diagnostics holds great potential in addressing many current clinical unmet needs to ultimately improve patient outcomes in a value-based manner.

How our biomarker diagnostics can support you

As a company with the highest regard for quality, we are ISO13485 certified, and both our commercial assays: the Merlin™ test and SKY92, have been certified to meet regulatory approval requirements such as the European CE-IVD mark, demonstrating compliance with quality and safety standards.

Our diagnostic assays are developed to be both scientifically robust and clinically meaningful.

The Merlin™ test

The Merlin™ test is in-licensed from and co-developed with Mayo Clinic (USA). It is commercially available in the United States and Europe. Merlin uses the proprietary CP-GEP algorithm to identify cutaneous melanoma (skin cancer) patients at low risk of having nodal metastasis who could forgo an invasive surgery under general anesthetics.


SKY92 is in-licensed from the Erasmus MC (Rotterdam, the Netherlands). It is commercially available in the United States and Europe. SKY92 calculates the risk of having an aggressive form of multiple myeloma (blood cancer) that might require a more intensive treatment regimen to increase the length of the remission.

0 +


We have formed strong partnerships with renowned institutes like Mayo Clinic, Erasmus MC, and Imperial College London, collaborating in various stages of diagnostic development.

0 +


With over 20 publications and growing our robust research contributes to the advancement of science, ultimately providing patients with better care.


dedicated R&D programs

Falcon (dermato-oncology), Panthera (hematology), and Delphia (infectious and inflammatory diseases) all focus on their respective disease areas to uncover and optimize the clinical pathway to the patient.

0 +

years of experience

With over 10 years of experience in molecular diagnostics, we lead innovation for personalized healthcare.

Partner with us

We believe that scientifically robust and clinically meaningful biomarkers should find their way to patients, therefore we don’t focus on one disease or group of diseases specifically. We encourage you to submit your biomarker discovery or your proposal to write a grant application with us. We are always open to new collaborations. Whether it regards collaborations to collect additional evidence on products already in our pipeline or collaborations outside our current R&D Programs.

Scroll to see more ›

Lab Operations Team

Our trusted collaborations

What others have to say about us

Get in touch with us

Service is a joy to us, so please do not hesitate to connect with us. We will make sure your message gets to the right person.